Clinical trial
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
NCT00161876 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161876 |
|---|---|
| Title | FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years |
| Official title | Open-label, Multicenter, Follow-up Phase III Study to Investigate the Safety of the Third Vaccination of FSME-IMMUN NEW in Volunteers Aged 16 to 66 Years |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Encephalitis, Tick-borne |
| Intervention type | Biological |
| Interventions | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
| Enrollment | 3,973 |
| Start date | May 1, 2002 |
| Completion | Aug 1, 2002 |
| First posted | Sep 13, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: